Open main menu
Home
Random
Donate
Recent changes
Special pages
Community portal
Preferences
About Stockhub
Disclaimers
Search
User menu
Talk
Contributions
Create account
Log in
Editing
SOMOS
(section)
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Market == === 1 drug alone is a $27B+ opportunity === SOMOS aims big. '''The total pharma market is $1.5T worldwide'''. Latinos represent 20% of the total US pharma sales, which contributes with more than '''$23bn'''. When we sequence genetic information for one disease alone (Non-alcoholic liver disease), SOMOS would still have a '''$27B+ market opportunity.''' The ancestry market will be our initial revenue driver. [[File:019172cbbd7d7d8c7b331a7d6f90550e8d5ed0f2.png]] Placing the disease addressable market aside, '''Latinos represent the fastest growing economy in the US, and 8th worldwide.''' Our product appeals to a '''$63B+ Total Pharma market in Latin America,''' which further ensures market stickiness. According to MIT and the current Latino population just in the US, we could expect '''18M Latinos''' taking a DNA ancestry test within the next 2 years. We plan to acquire '''5% of this market.''' Our initial goal: '''+500K''' Latinos on our platform by year 5, to accelerate research. [[File:F80a590c5be09d8f25b5eb70dc9a6755b65ecd31.png]]
Summary:
Please note that all contributions to Stockhub may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
Stockhub:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)